A Four-Year Experience of Symptomatic Intracranial Hemorrhage Following Intravenous Tissue Plasminogen Activator at a Comprehensive Stroke Center

      Background

      To describe the 4-year experience of symptomatic intracranial hemorrhage (sICH) rate at a high-volume comprehensive stroke center.

      Methods

      All admitted adult (≥18 years) patients presenting with an ischemic stroke from 2010 to 2013 were included in this study. The primary outcome was sICH, defined as any hemorrhage with neurological deterioration (change in National Institutes of Health Stroke Scale score ≥4) within 36 hours of intravenous tissue plasminogen activator (IV-tPA) treatment, or any hemorrhage resulting in death. Secondary outcomes were in-hospital mortality and having a favorable modified Rankin Scale (mRS) score (≤2).

      Results

      A total of 1925 did not receive intravascular (IV) or intra-arterial (IA) therapy; only 451 received IV therapy; and 175 received both IV and IA therapies. In IV-only patients, the overall rate of sICH was 2.2%; in IV and IA patients, the rate was 5.7%; and in patients who received no therapy, the rate was .4%. The IV-only group had an sICH rate of .9% in 2013. There were no differences in the adjusted odds of dying in the hospital between the study groups. IV-only treatment offered significantly better odds of achieving a favorable functional outcome, compared to no therapy, among patients with moderate stroke severity, whereas IV and IA treatments offered significantly better odds among patients with severe strokes. The odds of achieving a favorable functional outcome by discharge were decreased by 97% if patients suffered an sICH (OR = .03, 95%CI = .004, .19).

      Conclusions

      Despite an increased risk of sICH with IV-tPA, treatment with IV-tPA continues to be associated with increased odds of a favorable discharge mRS.

      Key Words

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kochanek K.
        • Murphy S.
        • Xu J.
        • et al.
        Mortality in the United States, 2013.
        (NCHS Data Brief, No 178: National Center for Health Statistics)2014
      1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
        (N Engl J Med)1995: 1581-1587 (333)
        • Nasr D.M.
        • Brinjikji W.
        • Cloft H.J.
        • et al.
        Utilization of intravenous thrombolysis is increasing in the United States.
        Int J Stroke. 2013; 8: 681-688
        • Lees K.R.
        • Bluhmki E.
        • von Kummer R.
        • et al.
        Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.
        Lancet. 2010; 375: 1695-1703
        • Group I.-C.
        The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): a randomised controlled trial.
        Lancet. 2012; 379: 2352-2363
        • Group I.-C.
        Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the Third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial.
        Lancet Neurol. 2013; 12: 768-776
        • Wahlgren N.
        • Ahmed N.
        • Dávalos A.
        • et al.
        Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.
        Lancet. 2007; 369: 275-282
        • Wahlgren N.
        • Ahmed N.
        • Davalos A.
        • et al.
        Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study.
        Lancet. 2008; 372: 1303-1309
        • Scheitz J.F.
        • Seiffge D.J.
        • Tutuncu S.
        • et al.
        Dose-related effects of statins on symptomatic intracerebral hemorrhage and outcome after thrombolysis for ischemic stroke.
        Stroke. 2014; 45: 509-514
        • Vujkovic Z.
        • Racic D.
        • Miljkovic S.
        • et al.
        Hemorrhagic complications of thrombolytic therapy.
        Med Pregl. 2012; 65: 9-12
        • Muchada M.
        • Rubiera M.
        • Rodriguez-Luna D.
        • et al.
        Baseline National Institutes of Health stroke scale-adjusted time window for intravenous tissue-type plasminogen activator in acute ischemic stroke.
        Stroke. 2014; 45: 1059-1063
        • Huang Y.H.
        • Zhuo S.T.
        • Chen Y.F.
        • et al.
        Factors influencing clinical outcomes of acute ischemic stroke treated with intravenous recombinant tissue plasminogen activator.
        Chin Med J. 2013; 126: 4685-4690
        • Broderick J.P.
        • Palesch Y.Y.
        • Demchuk A.M.
        • et al.
        Endovascular therapy after intravenous t-PA versus t-PA alone for stroke.
        N Engl J Med. 2013; 368: 893-903
        • Kono S.
        • Deguchi K.
        • Morimoto N.
        • et al.
        Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
        J Stroke Cerebrovasc Dis. 2013; 22: 190-196
        • Levy D.E.
        • Brott T.G.
        • Haley Jr, E.C.
        • et al.
        Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke.
        Stroke. 1994; 25: 291-297
        • Abilleira S.
        • Cardona P.
        • Ribo M.
        • et al.
        Outcomes of a contemporary cohort of 536 consecutive patients with acute ischemic stroke treated with endovascular therapy.
        Stroke. 2014; 45: 1046-1052
        • Nogueira R.G.
        • Yoo A.J.
        • Masrur S.
        • et al.
        Safety of full-dose intravenous recombinant tissue plasminogen activator followed by multimodal endovascular therapy for acute ischemic stroke.
        J Neurointerv Surg. 2013; 5: 298-301
        • Larrue V.
        • von Kummer R.
        • Muller A.
        • et al.
        Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).
        Stroke. 2001; 32: 438-441
        • Lorenzano S.
        • Ahmed N.
        • Falcou A.
        • et al.
        Does sex influence the response to intravenous thrombolysis in ischemic stroke?: answers from safe implementation of treatments in Stroke-International Stroke Thrombolysis Register.
        Stroke. 2013; 44: 3401-3406
        • Ahmed N.
        • Wahlgren N.
        • Brainin M.
        • et al.
        Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR).
        Stroke. 2009; 40: 2442-2449
        • Wardlaw J.M.
        • Murray V.
        • Berge E.
        • et al.
        Thrombolysis for acute ischaemic stroke.
        Cochrane Database Syst Rev. 2014; (CD000213)
        • Haley E.C.
        • Brott T.G.
        • Sheppard G.L.
        • et al.
        Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group.
        Stroke. 1993; 24: 1000-1004
        • Hacke W.
        • Kaste M.
        • Bluhmki E.
        • et al.
        Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
        N Engl J Med. 2008; 359: 1317-1329
        • Scott P.A.
        • Meurer W.J.
        • Frederiksen S.M.
        • et al.
        A multilevel intervention to increase community hospital use of alteplase for acute stroke (INSTINCT): a cluster-randomised controlled trial.
        Lancet Neurol. 2013; 12: 139-148
        • del Zoppo G.J.
        • Poeck K.
        • Pessin M.S.
        • et al.
        Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke.
        Ann Neurol. 1992; 32: 78-86
        • Heron M.
        Deaths: Leading Causes for 2008.
        (National Vital Statistics Reports: US Department of Health and Human Services)2012